March 26, 2025 at 2PM EST

Preparing to launch an HCP-administered treatment can be one of the most challenging opportunities for manufacturer commercial teams in their careers. HCP-administered products require use of a completely different “playbook” and “commercialization rules” (compared to self-administered treatments) given the dynamics of buy and bill among sites of administration and ASP-based reimbursement. The playbook and rules have far-reaching implications for how a manufacturer should develop its pre-commercialization strategy, encompassing almost all areas of market access. In this webinar we provided an overview of the HCP-administered playbook and essential considerations for manufacturers who are preparing to launch an HCP-administered specialty or orphan / rare product. Specific topics covered included: 

• Importance of ASP-Stewardship and Site of Administration Net Cost Recovery  
• Essential Considerations for Design of a Product’s Pricing Strategy, Payer Strategy, Channel Strategy, Patient Services Strategy, and Discounting / Rebating Strategy  
• Gross-to-Net and Government Pricing Considerations 
• Scenarios and Conditions for When the Playbook and Rules May Not Apply 

Joey Miller
Senior Principal

Brett Casper
Senior Principal